Abbott Laboratories (ABT) Panoramica del titolo
Abbott Laboratories, insieme alle sue consociate, scopre, sviluppa, produce e vende prodotti sanitari in tutto il mondo. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 3/6 |
| Crescita futura | 2/6 |
| Prestazioni passate | 2/6 |
| Salute finanziaria | 3/6 |
| Dividendi | 5/6 |
ABT Community Fair Values
Create NarrativeSee what 281 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$113.88
FV
7.2% sottovalutato sconto intrinseco6.57%
Revenue growth p.a.
255
users have viewed this narrative2users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
Concorrenti di Abbott Laboratories
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$105.70 |
| Massimo di 52 settimane | US$137.49 |
| Minimo di 52 settimane | US$81.97 |
| Beta | 0.61 |
| Variazione di 1 mese | 14.67% |
| Variazione a 3 mesi | 18.15% |
| Variazione di 1 anno | -16.96% |
| Variazione a 3 anni | -1.81% |
| Variazione a 5 anni | -13.48% |
| Variazione dall'IPO | 28,763.14% |
Notizie e aggiornamenti recenti
Aggiornamento narrativa • Jul 23
ABT: Cancer Diagnostics Expansion And Dividend Streak Will Drive Future Repricing
Abbott Laboratories' fair value estimate has moved from $116.54 to $119.13. This reflects analysts' higher price targets in the $112 to $121 range after Q2 results that were viewed as better than expected and supported by updated models and confidence in longer term growth drivers.Seeking Alpha • Jul 16
Abbott Laboratories: Double Beat And Raise Surprises The Street (Rating Upgrade)
Summary Abbott Laboratories delivered strong Q2 results, beating expectations and raising FY 2026 guidance, prompting a 14% stock surge. ABT’s valuation now appears fair, with normalized EPS estimated at $5.80 and an 18x P/E suggesting near-term value around $105. Key segments like diagnostics and electrophysiology posted robust growth, while shareholder returns totaled $2.1 billion in Q2. I’m upgrading ABT to Hold; technicals are mixed, but profitability, yield, and pipeline progress support a neutral stance post-earnings. Read the full article on Seeking AlphaRecent updates
Aggiornamento narrativa • Jul 23
ABT: Cancer Diagnostics Expansion And Dividend Streak Will Drive Future Repricing
Abbott Laboratories' fair value estimate has moved from $116.54 to $119.13. This reflects analysts' higher price targets in the $112 to $121 range after Q2 results that were viewed as better than expected and supported by updated models and confidence in longer term growth drivers.Seeking Alpha • Jul 16
Abbott Laboratories: Double Beat And Raise Surprises The Street (Rating Upgrade)
Summary Abbott Laboratories delivered strong Q2 results, beating expectations and raising FY 2026 guidance, prompting a 14% stock surge. ABT’s valuation now appears fair, with normalized EPS estimated at $5.80 and an 18x P/E suggesting near-term value around $105. Key segments like diagnostics and electrophysiology posted robust growth, while shareholder returns totaled $2.1 billion in Q2. I’m upgrading ABT to Hold; technicals are mixed, but profitability, yield, and pipeline progress support a neutral stance post-earnings. Read the full article on Seeking AlphaArticolo di analisi • Jun 21
Abbott Laboratories (ABT) Stock Could Be 24% Below Fair Value Before Earnings
Dividend affirmation and earnings catalyst put Abbott Laboratories stock in focus Recent commentary on Abbott Laboratories (ABT) has centered on upcoming earnings and Citi highlighting the value of its diversified healthcare businesses, setting the stage for closer attention to the stock. The reaffirmed quarterly dividend and the approaching July 16 earnings report give investors timely reference points as they weigh Abbott Laboratories stock, its current business mix, and expectations around...Aggiornamento narrativa • Jun 16
ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing
Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower from about $117.29 to $116.54, reflecting a series of reduced Street price targets that cite utilization and inflation headwinds, while still applying a modestly lower discount rate and a slightly softer future P/E assumption. Analyst Commentary Recent Street research on Abbott Laboratories points to a more cautious tone, with many price targets cut and utilization and inflation flagged as key issues.Aggiornamento narrativa • Jun 02
ABT: Cancer Diagnostics Expansion And Dividend Streak Will Support Future Repricing
Analysts have nudged their fair value estimate for Abbott Laboratories slightly lower to about $117.29 from $118.64. This reflects a series of reduced price targets and more cautious outlooks on growth and valuation across recent research updates.Aggiornamento narrativa • May 12
ABT: Medtech Pipeline And Dividend Record Will Support Future Repricing
Analysts have trimmed Abbott Laboratories' consolidated price target by $1, reflecting a slightly higher discount rate, a marginally lower revenue growth outlook, a very small adjustment to profit margin assumptions, and a modestly lower future P/E multiple in light of several recent target cuts and a removal from a conviction list. Analyst Commentary Recent Street research on Abbott Laboratories has tilted more cautious, with a series of price target reductions and a removal from a major conviction list.Aggiornamento narrativa • Apr 23
ABT: AF Portfolio And Dividend Track Record Will Support Future Repricing
Analysts have trimmed Abbott Laboratories' implied fair value estimate to $118.64 from $131.44. This reflects a series of recent price target reductions as they factor in updated growth, margin and P/E assumptions.Aggiornamento narrativa • Apr 09
ABT: AF Portfolio And Dividend Track Record Will Support Future Upside
Abbott Laboratories' updated analyst price target reflects a modest reset, with fair value moving from $132.64 to $131.44 as analysts factor in higher assumed revenue growth of 10.24%, a lower profit margin of 15.60% and a slightly richer future P/E of 30.91x. Analyst Commentary Recent research on Abbott Laboratories points to an active debate around how much investors should pay for the stock, with several price target changes clustered over the past few months.Aggiornamento narrativa • Mar 26
ABT: AF Portfolio Advancements And Dividend Streak Will Support Future Upside
Analysts have trimmed Abbott Laboratories' fair value estimate by about $0.70 to $132.64. This reflects a series of recent target cuts across the Street, even as they continue to reference generally healthy medtech sector fundamentals.Aggiornamento narrativa • Mar 11
ABT: AF Portfolio Progress And Dividend Streak Will Drive Future Upside
Analysts have trimmed their average price targets on Abbott Laboratories by a few dollars, reflecting slightly higher required returns and refreshed assumptions on fair value, while still grounding their views in recent research that includes both target cuts and at least one upward revision. Analyst Commentary Recent research on Abbott Laboratories gives you a mixed but useful read on how the Street is thinking about valuation, execution, and growth.Aggiornamento narrativa • Feb 24
ABT: Exact Sciences Deal And AF Portfolio Will Reshape Future Upside
Analyst targets on Abbott Laboratories have moved lower by double digit dollar amounts, with multiple firms trimming their price objectives in U.S. dollars as they factor in updated assumptions on discount rates, long term revenue growth, margins and future P/E expectations. Analyst Commentary Recent Street research on Abbott Laboratories reflects a mix of caution on valuation and optimism around the company’s longer term positioning, with several firms resetting price targets and one firm upgrading the stock.Aggiornamento narrativa • Feb 10
ABT: Exact Sciences Deal Will Reshape Testing Franchise And Future Upside
Analysts have trimmed their fair value estimate for Abbott Laboratories by about $3 to roughly $133. This reflects modestly softer revenue growth assumptions, a slightly lower future P/E multiple near 30x, and recent reductions in price targets across several firms, even as some still highlight the pending Exact Sciences deal as a key part of their thesis.Aggiornamento narrativa • Jan 26
ABT: Exact Sciences Acquisition Will Shape Future Earnings Mix And Upside Potential
Analysts have reduced their fair value estimate for Abbott Laboratories by about $8 to $136.47, reflecting a series of recent price target cuts that incorporate slightly adjusted growth, discount rate and P/E assumptions, along with expectations for a modestly higher profit margin profile. Analyst Commentary Recent research updates show a mix of optimism and caution around Abbott Laboratories, with several firms adjusting price targets and factoring in the pending Exact Sciences acquisition.Aggiornamento narrativa • Jan 11
ABT: Exact Sciences Deal And Legal Wins Will Support Future Upside
Narrative Update Overview The updated analyst work on Abbott Laboratories reflects a small increase in the implied fair value to about $144.75. Analysts point to a tighter discount rate, steady growth and margin assumptions, and a blended view of recent price target changes that factor in medical devices momentum, the pending Exact Sciences deal, and reduced legal overhangs.Articolo di analisi • Jan 03
Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...Aggiornamento narrativa • Dec 27
ABT: Exact Sciences Deal And Legal Wins Will Drive Future Returns
Analysts modestly raised their average price target for Abbott Laboratories to about $144 per share, citing resilient mid-single digit organic revenue growth, double digit earnings power supported by a diversified healthcare portfolio, accelerating momentum in Medical Devices despite some near term lumpiness, and potential strategic upside from the pending Exact Sciences acquisition at a premium takeout valuation. Analyst Commentary Street research remains broadly constructive on Abbott, with recent notes highlighting both upside drivers and areas of near term scrutiny as investors digest the Exact Sciences transaction and mixed quarterly optics.Aggiornamento narrativa • Dec 12
ABT: Exact Sciences Deal And Legal Wins Will Drive Future Upside
Analysts made a modest adjustment to their Abbott Laboratories price targets, with estimates moving in a roughly $2 range around the mid-$140s as they balanced optimism around the pending Exact Sciences acquisition, resilient device driven growth, and favorable legal developments against some near term lumpiness in non device segments. Analyst Commentary Research coverage around Abbott remains largely constructive, with most views anchored on a durable devices growth profile, incremental benefits from the proposed Exact Sciences transaction, and diminishing legal overhangs.Aggiornamento narrativa • Nov 28
ABT: Exact Sciences Acquisition And Legal Wins Will Drive Medium-Term Upside
Abbott Laboratories’ analyst price target saw a modest decrease to $144.43 as analysts point to shifting expectations around profit margin and a slightly higher discount rate. This development is tempered by optimism for ongoing revenue growth and stability in core medical device performance.Aggiornamento narrativa • Nov 14
ABT: Momentum From Legal Win And Product Approvals Will Support Future Gains
Analysts have modestly revised their price targets for Abbott Laboratories, with recent updates ranging from $142 to $146 per share. They cite strong momentum in Medical Devices and a resilient, diversified business model, despite varied performance across business segments.Articolo di analisi • Nov 05
Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem
Abbott Laboratories ( NYSE:ABT ) announced strong profits, but the stock was stagnant. Our analysis suggests that...Aggiornamento narrativa • Oct 31
ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead
Abbott Laboratories' average analyst price target experienced a modest increase to approximately $144.47. Analysts cited positive legal developments and continued momentum in the Medical Devices segment as key factors supporting the adjustment.Aggiornamento narrativa • Oct 16
Expanding Emerging Markets And Diagnostics Will Drive Prospects Despite Headwinds
Analysts have modestly increased their price target for Abbott Laboratories from $142.48 to $144.40, citing resilient growth in medical devices and expectations for steady double-digit earnings growth, even though there may be some near-term variability across business segments. Analyst Commentary Recent research notes reflect a mix of optimism and caution from analysts following Abbott Laboratories' latest results and updates to price targets.Articolo di analisi • Sep 15
There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings
With a price-to-earnings (or "P/E") ratio of 16.7x Abbott Laboratories ( NYSE:ABT ) may be sending bullish signals at...Seeking Alpha • Apr 16
Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices
Summary I reiterate a "Strong Buy" rating on Abbott Laboratories, driven by strong growth in medical device and pharma markets, with a fair value of $160 per share. Abbott reported 6.9% organic revenue growth and 8.3% growth excluding COVID testing, driven by 12.6% growth in medical devices and 7.8% in pharma. Abbott's diversified global supply chain and 25 new products in the pipeline position it well to navigate tariff impacts and drive future growth. Despite geopolitical risks in China, Abbott's cost management and margin expansion support the ABT stock double-digit EPS growth guidance for FY25. Read the full article on Seeking AlphaRendimenti per gli azionisti
| ABT | US Medical Equipment | US Mercato | |
|---|---|---|---|
| 7D | 2.6% | 3.9% | 0.8% |
| 1Y | -17.0% | -14.4% | 19.1% |
Ritorno vs Industria: ABT ha avuto una performance inferiore rispetto al US Medical Equipment che ha registrato un rendimento -14.4 % nell'ultimo anno.
Rendimento vs Mercato: ABT ha avuto una performance inferiore al mercato US che ha registrato un rendimento 19.1 % nell'ultimo anno.
Volatilità dei prezzi
| ABT volatility | |
|---|---|
| ABT Average Weekly Movement | 4.9% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: ABT non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 5% ) di ABT è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 1888 | 115,000 | Robert Ford | www.abbott.com |
Abbott Laboratories, insieme alle sue controllate, scopre, sviluppa, produce e vende prodotti sanitari in tutto il mondo. Opera in quattro segmenti: Prodotti farmaceutici consolidati, Prodotti diagnostici, Prodotti nutrizionali e Dispositivi medici. L'azienda offre prodotti farmaceutici generici per il trattamento dell'insufficienza pancreatica esocrina, della sindrome dell'intestino irritabile o dello spasmo biliare, della colestasi intraepatica o dei sintomi depressivi, dei disturbi ginecologici, della terapia ormonale sostitutiva, della dislipidemia, ipertensione, ipotiroidismo, ipertrigliceridemia, malattia di Ménière e vertigini vestibolari, dolore, febbre, infiammazione ed emicrania, oltre a fornire antinfettivi come la claritromicina, il vaccino antinfluenzale e prodotti per regolare il ritmo fisiologico del colon.
Abbott Laboratories Riepilogo dei fondamenti
| ABT statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$182.75b |
| Utili (TTM) | US$5.40b |
| Ricavi(TTM) | US$46.59b |
33.9x
Rapporto P/E3.9x
Rapporto P/SABT è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| ABT Conto economico (TTM) | |
|---|---|
| Ricavi | US$46.59b |
| Costo del fatturato | US$20.10b |
| Profitto lordo | US$26.48b |
| Altre spese | US$21.08b |
| Utili | US$5.40b |
Ultimi utili riportati
Jun 30, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | 3.12 |
| Margine lordo | 56.85% |
| Margine di profitto netto | 11.59% |
| Rapporto debito/patrimonio netto | 63.2% |
Come si è comportato ABT nel lungo periodo?
Vedi performance storica e confrontoDividendi
2.4%
Rendimento attuale del dividendo80%
Rapporto di remunerazioneABT paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di ABT| Abbott Laboratories date dei dividendi | |
|---|---|
| Data di stacco del dividendo | Jul 15 2026 |
| Data di pagamento dei dividendi | Aug 17 2026 |
| Giorni fino al dividendo Ex | 17 days |
| Giorni prima della data di pagamento dei dividendi | 16 days |
ABT paga dividendi affidabili?
Vedere la storia dei dividendi e i benchmark di ABTAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/31 04:03 |
| Prezzo dell'azione a fine giornata | 2026/07/31 00:00 |
| Utili | 2026/06/30 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Abbott Laboratories è coperta da 51 analisti. 26 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| David Toung | Argus Research Company |
| David Rescott | Baird |
| Adam Feinstein | Barclays |